Atos | June 07, 2021
Atos and Huma, a digital health innovator, has announced a five-year strategic global partnership to move healthcare and clinical trials out of hospitals and people's homes. The partnership will center on Huma's modular platform, which can power digital "home hospitals" nationally and assist pharmaceutical and research industries in running sophisticated worldwide, decentralized clinical trials. The platform is already being used in the United States and Europe to treat illnesses ranging from atrial fibrillation to diabetes to Covid-19.
To accelerate the adoption of Huma's technology, Atos will use its experience in delivering and scaling complex transformation projects. Atos will make an investment of up to €20 million in R&D and go-to-market resources, including dedicated consulting and sales personnel. The R&D investment will accelerate the integration of the Huma platform with other leading clinical platforms and develop a dedicated video module.
The immense pressure put on the world's healthcare systems by the Covid-19 pandemic exposes the flaws of current models, which are already overloaded aging populations and the increased worldwide incidence of chronic conditions. To improve both patient care and the entire efficiency of the care chain, innovation is required. The approach used by Atos and Huma means that patients are monitored outside of the hospital and get early, proactive clinical intervention ahead of need, ultimately optimizing resource use, improving patient outcomes, and reducing long-term healthcare costs.
Early evidence suggests that Huma's service, which is now available nationally in Germany, England, and the UAE, can almost double hospital capacity.
The partnership will use Huma's industry-leading software platform and 40+ patents and Atos' extensive professional service capabilities in digital strategy, change management, and service management.
The 5-year partnership will begin with integration, enabling global go-to-market deployments. Still, it will also combine Atos' expertise in promoting digital adoption, support, and infrastructure with Huma's digital care, clinical trials, and biomarkers. The companies estimate that the combined service will generate €100 million in revenue per year during the first four years.
With 105,000 employees and annual revenue of more than € 11 billion, Atos is a global leader in digital transformation. The Group, the European leader in cybersecurity, cloud, and high-performance computing, provides customized end-to-end solutions for all industries in 71 countries. Atos, a pioneer in decarbonization services and products, is dedicated to providing its clients with a safe and decarbonized digital experience. Atos is recognized by the brands Atos and Atos|Syntel.
Huma is a global health technology company that helps people to live longer and more fulfilling lives. Our modular platform enables digital 'hospitals at home' in a variety of disease areas. We power some of the world's most extensive decentralized clinical trials and studies in life sciences. To promote proactive, predictive care and research, our platform combines artificial intelligence, digital biomarkers, and real-world data.
QPharma | June 08, 2021
QPharma, a Medical, Commercial, and Compliance services leader for the life sciences sector,announcedthe establishment of Neolytica, a subsidiary that will elevate healthcare analytics to new heights.
For the past 25 years, QPharma has been a compliance pioneer. It has recently achieved tremendous success and traction in healthcare analytics, notably Ti Expert (KOL mapping and HCP targeting) solution, and NotifyMe product. This is one of the primary motivators for establishing Neolytica, which will focus on platforms and solutions that will use next-generation technologies such as NLP, AI, Face recognition, and Chatbots to amplify the much-needed technological advancement in the healthcare community, particularly for Medical Affairs/MSL insights, Marketing, and Commercial teams.
A substantial portion of QPharma's success is its ability to detect industry gaps and develop unique solutions to bridge them. QPharma's decision to focus on and invest in data analytics and AI complements its expertise in the pharmaceutical industry. The result is a healthcare analytics-focused portfolio of innovative products and solutions. A complete offering that will enable clients to obtain intuitive insights through the use of itsplatforms.
Neolytica's solutions and product portfolio, backed by award-winning leadership and well supported by a worldwide team of industry experts, will bring considerable value in the strategic and operational areas of Medical Affairs, Market Access, Commercial Marketing, and Commercial Sales.
About QPharma, Inc.
QPharma, which was founded in 1994, is the industry leader in cloud-based software and services for the life sciences. Its Commercial Services division offers sample management and distribution, product launch management, online training, and HCP/KOL targeting and engagement solutions. Validation services, project management, auditing, and training are among the services provided by the company's Professional Services division. QPharma is also an official American Medical Association Database Licensee and a National Association of Boards of Pharmacy Verified Accredited Wholesale Distributor.
Biostrap | November 20, 2021
LCA Vantage Healthcare Corporation ("LCAV"), an innovative technology company, partners with Biostrap USA LLC ("Biostrap"), a digital health solutions company, to provide the world's first Electronic Health Record (EHR) and overall SMART Tract® Health system that integrates continuous biometric monitoring to improve patient care and overcome administrative and technological challenges.
Advancing health care into the next century, LCAV created a full-stack, Fast Healthcare Interoperability Resources (FHIR) compliant, cloud-based digitized medical product and service, Parker System®, which consolidates every piece of data for individual patients, emergency services and hospital networks under one umbrella.
LCAV and Biostrap will be the first to provide continuous and non-invasive monitoring of patients' biometrics in accordance with new CMS, FHIR and FDA regulations and policies.
"Our partnership is very exciting for the continuous development and deployment of real-world solutions. For generations, the EHR systems have struggled to innovate and keep up with modern day medicine," said Vince Lopez, Founder and CEO of LCAV, noting that "Biostrap is the only wearable product on the market that aligns with LCAV's mission and technical solution to advance health care accessibility, diagnostic testing and monitoring and ongoing clinical research. This is the future!"
Achieving interoperability, that is finding, sending, receiving and integrating electronic patient information from outside providers, has been a challenge for most hospitals in sharing patient data. According to a recent Health Affairs study, only 29.7 percent of hospitals engaged in all four domains of interoperability in 2015. However, the gap between patient care and health care efficiency has been overlooked.
EHR systems play a vital role in improving patient safety by reducing medical errors and exaggerated costs. With the adoption of advanced digital health solutions and remote physiological monitoring technologies, the need for a reliable and secure EHR system and biometric monitoring integration is critical to improve quality of care, patient outcomes and decrease hospital readmissions. This has never been done, until now.
The partnership between LCAV and Biostrap will revolutionize health care for generations to come. The solution streamlines interoperability, automation, accessibility and advanced clinical research by leveraging health data across the continuum of care.
The momentum of digital health shows an upward trend. According to a Global Market Insights report, the global digital health market is projected to surpass $379 billion by 2024.
This partnership demonstrates the impact of two progressive science and technology companies working together to solve a global problem. For the first time in the history of medicine, patients and clinicians will be empowered with instantaneous access to valuable health data across the continuum of care through robust artificial intelligence and machine learning.
"When I founded Biostrap, my goal was not to develop another shiny fitness gadget with limited utility, but to combine my passion for health and technology into a product with the potential to meaningfully impact human health. Our partnership with LCAV will truly revolutionize the health care system by improving accessibility to clinical-grade data and making it simultaneously available and actionable to health care professionals through the Parker System."
Sameer Sontakey, Chief Executive Officer of Biostrap
Biostrap is a progressive digital health solutions provider pioneering the industry of medical biosensors, data processing techniques, and remote physiological monitoring (RPM) workflows. By developing, owning, and operating the entire digital stack, Biostrap provides custom solutions for enterprise markets including decentralized clinical research, government organizations, health care institutions and the space industry. Biostrap has a dedicated team of health care professionals, data scientists, engineers and hardware specialists with a proven ability to deliver complex, integrated digital health solutions.
ABOUT LCA VANTAGE HEALTHCARE CORPORATION
LCA Vantage Healthcare Corporation (LCAV) is an innovative research and technology company accelerating health care into the next century. LCAV is designed and committed to simplifying the complexities of health care, while putting the power of choice and affordability back into the hands of its patients and clinical users 24/7/365. The Parker System ® is the only customizable full-stack, cloud-based EHR and SaaS medical product that exceeds FHIR regulatory compliance. Parker consolidates every stream of patient data through secure multi-factor encryption with real-time communication to emergency services, providers, hospital networks, payers, research and government institutions.